Hutchison China MediTech (Chi-Med) has started a global Phase I/Ib study of its novel small molecule Syk inhibitor in patients with relapsed or refractory lymphoma. The primary endpoints of the trial are safety and tolerability, though PK and objective response rates will also be monitored. Chi-Med expects that HMPL-523, a second-gen Syk inhibitor, will cause fewer safety problems than first-gen candidates. In an earlier Australian trial, HMPL-523 showed an acceptable safety profile. The candidate is also being tested in a China Phase I trial in patients with immune thrombocytopenia.
Source: China Biotoday
